<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01232504</url>
  </required_header>
  <id_info>
    <org_study_id>L-09-01</org_study_id>
    <nct_id>NCT01232504</nct_id>
  </id_info>
  <brief_title>Antifungal Effects of rhGM-CSF in Patients After Allo-HSCT</brief_title>
  <official_title>Antifungal Effects of Recombinant Human Granulocyte Macrophage Colony Stimulating Factor in Patients After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiamen Amoytop Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xiamen Amoytop Biotech Co., Ltd.</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-center, open, parallel and controlled clinical study to
      evaluate the antifungal effects of rhGM-CSF in patients who have already received Allo-HSCT.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification:  Safety/Efficacy Study, Intervention Model:  Parallel Assignment, Masking:  Open Label, Primary Purpose:  Prevention</study_design>
  <primary_outcome>
    <measure>Incidence of fungal infection after Allo-HSCT</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of fungal infection during 100 days after Allo-HSCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of SFI and the clearance rate of fungi</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of SFI and the clearance rate of fungi in patients during 100 days after Allo-HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery of white blood cell and PLT</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recovery of white blood cell and PLT in patients during 100 days after Allo-HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant related mortality</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Transplant related mortality of patients during 100 days after Allo-HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of GVHD</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of GVHD in patients during 100 days after Allo-HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence rate of primary disease</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Recurrence rate of primary disease in patients during 100 days after Allo-HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overall survival rate in patients during 100 days after Allo-HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mucositis</measure>
    <time_frame>100 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Conditions of mucositis in patients during 100 days after Allo-HSCT.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fungal Infection After Allogeneic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>rhGM-CSF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-7μg/kg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhGM-CSF plus rhG-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rhGM-CSF and rhG-CSF both at 2-3μg/kg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rhG-CSF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-7μg/kg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhGM-CSF</intervention_name>
    <description>5-7μg/kg daily subcutaneously（sc）without interruption until neutrophils≥1.5×10(9)/L for two continuous days,starting 5 days after transplantation.</description>
    <arm_group_label>rhGM-CSF</arm_group_label>
    <other_name>Topleucon</other_name>
    <other_name>Granulocyte Macrophage Colony Stimulating Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhG-CSF</intervention_name>
    <description>5-7μg/kg daily subcutaneously（sc）without interruption until neutrophils≥1.5×10(9)/L for two continuous days,starting 5 days after transplantation.</description>
    <arm_group_label>rhG-CSF</arm_group_label>
    <other_name>Granulocyte Colony Stimulating Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rhGM-CSF plus rhG-CSF</intervention_name>
    <description>rhGM-CSF and rhG-CSF (both at 2-3μg/kg/d) subcutaneously（sc）without interruption until neutrophils≥1.5×10(9)/L for two continuous days,starting 5 days after transplantation.</description>
    <arm_group_label>rhGM-CSF plus rhG-CSF</arm_group_label>
    <other_name>Granulocyte Macrophage Colony Stimulating Factor</other_name>
    <other_name>Granulocyte Colony Stimulating Factor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Allogenic hematological stem cell transplantation(HSCT) patients.

          -  No serious damage to heart, liver and kidney function(TBIL≤34μmol/L, Cr≤120μmol/L, a
             normal EF).

          -  Informed consent.

        Exclusion Criteria:

          -  Patients were receiving anti-fungal treatment with proven SFI before transplantation.

          -  Allergic to rhGM-CSF or rhG-CSF.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai First People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <lastchanged_date>July 10, 2011</lastchanged_date>
  <firstreceived_date>October 25, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Shanghai First People's Hospital</name_title>
    <organization>Shanghai First People's Hospital</organization>
  </responsible_party>
  <keyword>Allo-HSCT</keyword>
  <keyword>rhGM-CSF</keyword>
  <keyword>Systemic fungal infection (SFI)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antifungal Agents</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Molgramostim</mesh_term>
  </intervention_browse>
</clinical_study>
